Patent ID: 7829064

Claim:
A method for treating a disease or disorder comprising administering to a patient a therapeutic composition comprising (i) one or more anti-CD74 antibodies or antigen-binding fragments thereof reactive with the epitope of CD74 to which the LL1 antibody binds, wherein the anti-CD74 antibodies or antigen-binding fragments thereof are covalently bound to the PEG component of a PEG-lipid conjugate incorporated into a liposome; wherein one or more effectors are incorporated into the liposome in unmodified active form, or covalently bound to the lipid component of the liposome, or covalently bound to the PEG component of the liposome; wherein said anti-CD74 antibodies are chimeric, human or humanized; wherein the anti-CD74 antibody or antigen-binding fragment thereof is an anti-CD74 diabody, a triabody, tetrabody or an scFv, and, (ii) a pharmaceutically acceptable excipient, wherein the cells of the patient that are associated with the disease or disorder are CD74-expressing cells.